Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Gynecol Cancer ; 14(4): 600-6, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15304153

RESUMO

OBJECTIVE: The aim of this study was to investigate whether the ovulation induction has relation with postneoplastic lesions. MATERIALS AND METHODS: Seventy-eight female, 90-day-old rats were enrolled for the trial. They were divided into three groups. In the first group, 13 rats received one cycle of ovulation induction with Follitropin Beta and human chorionic gonadotropin. The second group of 13 rats received three cycles of ovulation induction, and the third study group consisted of 13 rats which received six cycles of ovulation induction. Each group had a control group consisting of same number of rats that had not received ovulation induction. At the 12th month after the ovulation induction protocols ended, rat ovaries were extirpated for histopathological examination. In histopathological examination, malignant lesions, ovarian cyst and cyst diameter, epithelial stratification, epithelial tufting, mitotic index, polymorphism of epithelial cells and nucleus, epithelial cell nuclear diameter, chromatin density nuclear atypia, and mitotic activity in ovarian cyst epithelium were evaluated. RESULTS: No malignant ovarian lesion was found in the three groups. Ovarian cyst development was most frequent in the rats that underwent six cycles of ovulation induction. Epithelial stratification and tufting were most frequent in the rats which underwent ovulation induction six times. Significant difference was found between induction and control groups in second and third groups for cellular and nuclear polymorphism, presence of nucleolus, and nuclear chromatin density. CONCLUSIONS: Although development of malignant lesion were not found in any of the rat ovaries after ovulation induction, increase in the prevalence of epithelial dysplasia especially with increase in the number of induction cycles shows that some ovarian pathologies can occur subsequent to ovulation induction.


Assuntos
Neoplasias Ovarianas/patologia , Ovário/patologia , Indução da Ovulação/efeitos adversos , Lesões Pré-Cancerosas/patologia , Animais , Transformação Celular Neoplásica/induzido quimicamente , Transformação Celular Neoplásica/patologia , Gonadotropina Coriônica/efeitos adversos , Feminino , Subunidade beta do Hormônio Folículoestimulante/efeitos adversos , Neoplasias Ovarianas/induzido quimicamente , Ovário/efeitos dos fármacos , Lesões Pré-Cancerosas/induzido quimicamente , Ratos
2.
Gynecol Obstet Invest ; 58(3): 140-4, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15205566

RESUMO

OBJECTIVE: To find out the effect of estradiol with progesterone for luteal phase support in IVF-ICSI cycles. MATERIALS AND METHODS: Patients were accepted for treatment in the ART unit of Selcuk University, Meram Faculty of Medicine, between January 2001 and March 2003. The study was done in a prospective manner. The age range of 252 women was 19-41 years and the total number of cycles was 310. All patients were treated with a long ovulation induction protocol. Patients were treated and divided into two groups in a randomized manner: group I used only 600 mg/day divided into three equal doses of micronized progesterone vaginally, and group II used transdermal estradiol 100 microg/day + 600 mg/day vaginal micronized progesterone. RESULTS: 310 ICSI cycles were carried out in 252 infertile couples between January 2001 and March 2003. From 22 of these cycles, oocytes were retrieved but no embryos were developed. In the remaining 288 cycles there were embryo transfers. All embryo development was achieved by ICSI treatment. In 148 out of 288 cycles, the luteal phase was supported only by vaginal micronized progesterone (group I). On the other hand, the remaining 140 cycles received vaginal micronized progesterone plus transdermal estradiol 100 microg/day (group II). The number of beta-hCG-positive results in group I and group II were 20 (13.5 %) and 54 (38.5%) respectively. CONCLUSION: Adding estradiol to progesterone for luteal phase support in ICSI-ET cycles may increase implantation and pregnancy rates.


Assuntos
Implantação do Embrião/efeitos dos fármacos , Estradiol/farmacologia , Infertilidade/tratamento farmacológico , Fase Luteal/efeitos dos fármacos , Resultado da Gravidez , Progesterona/farmacologia , Adulto , Transferência Embrionária , Estradiol/uso terapêutico , Feminino , Fertilização in vitro , Humanos , Infertilidade/terapia , Ciclo Menstrual/efeitos dos fármacos , Indução da Ovulação , Gravidez , Progesterona/uso terapêutico , Estudos Prospectivos , Injeções de Esperma Intracitoplásmicas
3.
Br J Anaesth ; 90(5): 659-64, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12697595

RESUMO

BACKGROUND: This study was designed to evaluate the effects of intrathecal isobaric bupivacaine 0.5% plus morphine and isobaric ropivacaine 0.5% plus morphine combinations in women undergoing Caesarean deliveries. METHOD: Twenty-five parturients received ropivacaine 15 mg and morphine 150 micro g (RM group) and twenty-five parturients received bupivacaine 15 mg and morphine 150 micro g (BM group) for spinal anaesthesia. Sensory and motor block, haemodynamics, postoperative analgesia, fetal outcomes, and side-effects were evaluated. RESULTS: Intrathecal bupivacaine-morphine and ropivacaine-morphine provided effective sensory anaesthesia and motor block. Time to reach complete motor block was shorter and time to complete recovery from motor block was longer in the BM group than the RM group (P<0.05). The time to regression of two dermatomes and time for the block to recede to the S2 dermatome were similar in both groups (P>0.05). Time to first complaint of pain and the mean total consumption of tenoxicam were similar in both groups (P>0.05). APGAR scores at 1 and 5 min were similar in the two groups, as were mean umbilical blood pH values (P>0.05). Hypotension and pruritus were the most common side-effects in both groups during the operation. CONCLUSION: Intrathecal isobaric ropivacaine 0.5% 15 mg plus morphine 150 micro g provides sufficient anaesthesia for Caesarean delivery. The ropivacaine-morphine combination resulted in shorter motor block, similar sensory and postoperative analgesia.


Assuntos
Analgesia Obstétrica/métodos , Anestesia Obstétrica/métodos , Raquianestesia/métodos , Anestésicos Combinados , Anestésicos Locais , Cesárea , Adulto , Amidas , Analgésicos Opioides , Bupivacaína , Método Duplo-Cego , Feminino , Hemodinâmica/efeitos dos fármacos , Humanos , Morfina , Dor Pós-Operatória/prevenção & controle , Gravidez , Estudos Prospectivos , Ropivacaina
4.
Arch Gynecol Obstet ; 267(2): 90-4, 2002 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-12439554

RESUMO

OBJECTIVE: To investigate of efficiency to corticosteroid treatment for prevention of respiratory distress syndrome and other prematurity complications. MATERIALS AND METHODS: One thousand and six babies born at 26-36(th) gestational age were investigated for following parameters; the development of respiratory distress syndrome, necessity of surfactant therapy, mean duration of daily ventillatory support, rates of Grade III or IV intraventricular hemorrhage, and periventricular leukomalacia, necrotizing enterocolitis, proven neonatal sepsis and neonatal death. Antenatal steroids were administered in the form of two 12-mg intramuscular doses of betamethasone 12 h apart as a total 24 mg in the 24 h and repeat courses of two 12 mg of betamethasone every 7 days after the first dose of the last course if undelivered. Babies were divided into 4 groups based on betamethasone TREATMENT: The first group or control group didn't received treatment; the second group received treatment and delivered within 12 h after first injection; the third group delivered 12-24 h after first injection; and fourth group delivered at least 24 h after first injection. The patients ongoing pregnancy at least 1 week were divided into two groups as a single dose and multiple courses in once a week. RESULTS: Significant difference for development of respiratory distress syndrome between fourth group and others was found (p=0.029). There were significant difference for respiratory distress syndrome rate in hypertensive and premature rupture of membranes groups between fourth group and control group (p=0.002, p=0.041). There weren't significant difference for RDS between repeat doses and single dose groups (p>0.05). CONCLUSION: Single dose corticosteroid is an effective treatment for the development of RDS and the prevention of other prematurity complications.


Assuntos
Betametasona/uso terapêutico , Glucocorticoides/uso terapêutico , Doenças do Recém-Nascido/etiologia , Doenças do Recém-Nascido/prevenção & controle , Recém-Nascido Prematuro , Síndrome do Desconforto Respiratório do Recém-Nascido/prevenção & controle , Adulto , Betametasona/administração & dosagem , Esquema de Medicação , Feminino , Glucocorticoides/administração & dosagem , Humanos , Recém-Nascido , Injeções Intramusculares , Gravidez
5.
Arch Gynecol Obstet ; 266(3): 141-4, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12197552

RESUMO

The purpose of this study was to evaluate the efficacy of methyldopa in the treatment of preeclamptic patients. This study was performed on 24 preeclamptic women who were in between 25-36 weeks of gestational age. 24 healthy pregnant women were taken as control group. Before starting treatment, 24 preeclamptic patients were examined with Doppler ultrasound. Pulsatility index, resistance index, systolic/diastolic ratio of uterine, umblical and fetal middle cerebral arteries were measured. Preeclamptic patients were treated with totally 1 g methyldopa per day. After 7 d, patients were reexamined with Doppler ultrasound. The effect of methyldopa on uterine, umblical and fetal middle cerebral artery blood flows were detected. Only one control with Doppler ultrasound was done to the healthy pregnant women. Before methyldopa treatment to the preeclamptic women, pulsatility index (PI), resistance index (RI) and systolic/diastolic ratio (S/D) on uterine and umblical arteries were significantly higher than the control group. However, fetal middle cerebral artery (MCA) values were significantly lower than the control group. When Doppler results of preeclamptic patients before and after the methyldopa treatment were compared, no significant differences in terms of Pulsatility Index, Resistance IndexI and S/D ratio of umblical and fetal middle cerebral arteries were found. However, the results of uterine artery were significantly lower after the treatment in preeclamptic patients. Treatment with methyldopa lowered the uterine artery resistance in preeclamptic patients but did not effect the resistance of umblical and fetal middle cerebral artery.


Assuntos
Anti-Hipertensivos/farmacologia , Feto/irrigação sanguínea , Hemodinâmica/efeitos dos fármacos , Metildopa/farmacologia , Circulação Placentária/efeitos dos fármacos , Pré-Eclâmpsia/tratamento farmacológico , Adulto , Anti-Hipertensivos/uso terapêutico , Velocidade do Fluxo Sanguíneo , Feminino , Feto/efeitos dos fármacos , Humanos , Metildopa/uso terapêutico , Artéria Cerebral Média/diagnóstico por imagem , Artéria Cerebral Média/efeitos dos fármacos , Artéria Cerebral Média/fisiopatologia , Placenta/irrigação sanguínea , Placenta/diagnóstico por imagem , Placenta/efeitos dos fármacos , Pré-Eclâmpsia/diagnóstico por imagem , Pré-Eclâmpsia/fisiopatologia , Gravidez , Ultrassonografia Doppler , Ultrassonografia Pré-Natal , Artérias Umbilicais/diagnóstico por imagem , Artérias Umbilicais/efeitos dos fármacos , Artérias Umbilicais/fisiopatologia , Útero/irrigação sanguínea , Útero/diagnóstico por imagem , Útero/efeitos dos fármacos
7.
Arch Gynecol ; 240(2): 95-100, 1987.
Artigo em Inglês | MEDLINE | ID: mdl-3105474

RESUMO

Spironolactone was used in 90 hirsute women because of its antiandrogenic effect. The drug was administered twice daily from the 4th to the 22nd day of six cycles (total dosage was 200 mg per day). The results suggest that spironolactone is suitable for the treatment of hirsutism.


Assuntos
Hirsutismo/tratamento farmacológico , Espironolactona/uso terapêutico , 17-Cetosteroides/urina , Adolescente , Adulto , Feminino , Hormônio Foliculoestimulante/sangue , Humanos , Testosterona/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...